---
title: "IDEXX Laboratories: Q4 Earnings Insights"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274516406.md"
description: "IDEXX Laboratories (NASDAQ:IDXX) reported Q4 earnings on February 2, 2026, beating estimates with an EPS of $3.08, surpassing the $2.93 forecast by 5%. Revenue increased by $136.71 million year-over-year. The company also provided FY 2026 guidance, expecting earnings between $14.29 and $14.8 per share. Past performance shows a consistent trend of beating EPS estimates, although stock price changes can be influenced by guidance rather than just earnings results."
datetime: "2026-02-02T12:50:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274516406.md)
  - [en](https://longbridge.com/en/news/274516406.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274516406.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274516406.md) | [繁體中文](https://longbridge.com/zh-HK/news/274516406.md)


# IDEXX Laboratories: Q4 Earnings Insights

The Q4 earnings report for **IDEXX Laboratories** (NASDAQ:IDXX) was released on Monday, February 2, 2026 at 06:30 AM.

Here's what investors need to know about the latest announcement.

### Earnings

IDEXX Laboratories beat estimated earnings by 5.0%, reporting an EPS of $3.08 versus an estimate of $2.93.

Revenue was up $136.71 million from the same period last year.

### Past Earnings Performance

The company beat on EPS by $0.08 in the previous quarter, leading to a 0.0% increase share price change the next day.

Here's a look at IDEXX Laboratories's past performance:

**Quarter**

**Q3 2025**

**Q2 2025**

**Q1 2025**

**Q4 2024**

**EPS Estimate**

3.14

3.3

2.85

2.40

**EPS Actual**

3.22

3.5

2.91

2.53

**Revenue Estimate**

1.07B

1.07B

998.15M

936.68M

**Revenue Actual**

1.10B

1.11B

998.43M

954.29M

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

### Guidance

IDEXX Laboratories management provided guidance for FY 2026, expecting earnings between $14.29 and $14.8 per share.

To track all earnings releases for IDEXX Laboratories visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [iShares Genomics Immnlgy & Hlthcr ETF (IDNA.US)](https://longbridge.com/en/quote/IDNA.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [SPDR® S&P Health Care Equipment ETF (XHE.US)](https://longbridge.com/en/quote/XHE.US.md)
- [iShares US Healthcare Providers ETF (IHF.US)](https://longbridge.com/en/quote/IHF.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [IDEXX Laboratories, Inc. (IDXX.US)](https://longbridge.com/en/quote/IDXX.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [iShares US Medical Devices ETF (IHI.US)](https://longbridge.com/en/quote/IHI.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [Senti Biosciences Non-GAAP EPS of -$0.53 misses by $0.06](https://longbridge.com/en/news/280788653.md)
- [Idexx Laboratories (IDXX) Valuation Check After New Cancer Dx Panel Launch In The United Kingdom](https://longbridge.com/en/news/281429733.md)
- [Iterum Therapeutics Received Notice of Delisting](https://longbridge.com/en/news/281174211.md)
- [Caris Life Sciences, Inc. (NASDAQ:CAI) Receives Consensus Recommendation of "Hold" from Analysts](https://longbridge.com/en/news/281385092.md)
- [Zevenbergen Capital Investments LLC Invests $32.14 Million in Insulet Corporation $PODD](https://longbridge.com/en/news/281179756.md)